Biomerieux, Inc.

Hospices Civils De Lyon

Institut National De La Sante Et De La Recherche Medicale

Biomerieux Sa

Inserm (institut National De La Sante Et De La Recherche Medicale)

Bioaster

François Mallet

Bernard F Mandrand

Glaucia Paranhos-Baccala

Guillaume Monneret

Philippe Perot

Maud Arsac

Fabienne Venet

Alexandre Pachot

Nathalie Mugnier

Guy Oriol

Julien Textoris

Armelle Novelli-Rousseau

William McAllister

Jean-Philippe Pichon

Dimitri Lavillette

Bertrand Bonnaud

Catherine Ott

Laure Allard

Estelle Peronnet

Marine Mommert

Olivier Tabone

Cécile Montgiraud

Valérie Cheynet-Sauvion

Alessia Ruggieri

Jean-Luc Blond

Nadège Arnaud-Barbe

François-Loïc Cosset

Virginie Moucadel

Juliette Gimenez

Jérémy Becker

Thomas Rimmelé

Laurence Vachot

Laurence Generenaz

Valérie Cheynet

François-Loic Cosset

Olivier Bouton

Cécile Voisset

A method for determining in vitro or ex vivo the immune status of an individual, preferably a patient, including a step of detecting and/or quantifying the expression of one or more HERV/MaLR sequences in a biological sample of the individual. Also relates to the tools for implementing the method and to the uses thereof.

Method for determining in vitro or ex vivo the immune status of an individual

The subject matter of the present invention is a method for the diagnosis or prognosis, in vitro, of lung cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, a method for use of said nucleic acid sequences, which have been isolated, as a molecular marker or molecular markers, and a kit including at least one binding partner specific for at least one of the expression products of the HERV nucleic acid sequences.

Method for the diagnosis or prognosis, in vitro, of lung cancer

The subject matter of the present invention is a method for the diagnosis or prognosis, in vitro, of testicular cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said nucleic acid sequences, which have been isolated, as a molecular marker or molecular markers, and a kit including at least one binding partner specific for at least one of the expression products of the HERV nucleic acid sequences.

Method for the diagnosis or prognosis, in vitro, of testicular cancer

The present invention relates to a method for the in vitro diagnosis or prognosis of prostate cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said nucleic acid sequences, once isolated, as one or more molecular marker(s) and a kit comprising at least one specific binding partner of at least one of the expression products of the HERV nucleic acid sequences.

Method for the diagnosis or prognosis, in vitro, of prostate cancer

The present invention relates to a method for in vitro diagnosis or prognosis of colon cancer, including a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said isolated nucleic acid sequences as a molecular marker/molecular markers, and a kit including at least one specific binding partner for at least one expression product of the HERV nucleic acid sequences.

Method for in vitro diagnosis or prognosis of colon cancer

The present invention relates to a method for the in vitro diagnosis or prognosis of ovarian cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said nucleic acid sequences, once isolated, as one or more molecular marker(s) and a kit including at least one specific binding partner of at least one of the expression products of the HERV nucleic acid sequences.

Method for the in vitro diagnosis or prognosis of ovarian cancer

A method for estimating the affinity &#x3d5; of a first DNA strand, or 'probe', to be hybridized with a second DNA strand, or 'target', to form a hybrid of length L, the method comprising: in each division of a set of M divisions of the hybrid, counting the number of times in which each hybrid of a set of P DNA strand hybrids is present in the division, the hybrids being of length k less than the length L, or &#x201c;k-hybrids&#x201d;; for each combination of mismatches of a set of L combinations of mismatches in a hybrid of length Lbp, determining whether the pair of mismatches is present in the hybrid; and calculating the affinity &#x3d5; according to the relation: 

Method for estimating the probe-target affinity of a DNA chip and method for manufacturing a DNA chip

RNA may be transcribed using a nucleotide reagent as the promoter. The reagent may enable RNA to be transcribed without sequence specification and without protein cofactors, by means of an RNA polymerase that is known to be DNA-dependent such as the RNA polymerase of the phage T7, or by means of new, mutated RNA polymerase with the ability to synthesize a transcription product of polynucleotide matrix with a higher yield when the matrix is RNA than when the matrix is DNA. This type of RNA polymerase can be obtained by effecting mutations on a coding gene for a wild-type RNA polymerase, and then by selecting the mutated RNA polymerase with the ability. The invention can be applied notably to the detection, synthesis or quantification of RNA.

RNA-dependent RNA polymerase functioning preferably on a RNA matrix and promoter-dependent transcription process with said RNA-dependent RNA polymerase

Growing community of inventors

Villeurbanne, France

François Mallet